Century Medical Submits Cardica MicroCutter XCHANGE™ 30 Cartridge for Japanese Approval

Century Medical Submits Cardica MicroCutter XCHANGE™ 30 Cartridge for Japanese

PR Newswire

REDWOOD CITY, Calif. and TOKYO, Aug. 12, 2013

REDWOOD CITY, Calif. and TOKYO, Aug. 12, 2013 /PRNewswire/ -- Cardica, Inc.
(Nasdaq: CRDC) and Century Medical, Inc. today announced that Century Medical
filed for regulatory approval of Cardica's MicroCutter XCHANGE™ 30 cutting and
stapling cartridge in Japan. The submission to the Pharmaceuticals and Medical
Devices Agency (PMDA) includes design, validation and verification data for
the MicroCutter XCHANGE 30 cartridges. The XCHANGE 30 cartridges are used
together with the XCHANGE 30 device to perform surgical procedures.

"We believe that the MicroCutter XCHANGE 30, with its small size and
maneuverability, offers surgeons a significant advantage over conventional
staplers," said Mr. Akira Hoshino, President and Chief Executive Officer of
Century Medical, Inc. "We anticipate launching this revolutionary device in
Japan during 2014."

"Century Medical is an ideal partner for Cardica in Japan, with surgical
stapling expertise and product familiarity as our exclusive Japanese
distributor for the PAS-Port^® Proximal Anastomosis System," commented Bernard
A. Hausen, M.D., Ph.D., President and Chief Executive Officer of Cardica. "We
anticipate that Japan will become an important market for the MicroCutter
XCHANGE 30 due to the focus of Japanese surgeons on less invasive procedures."

About the MicroCutter XCHANGE 30
Cardica's MicroCutter XCHANGE 30 is available in select centers in Europe
today. The device has a cross-sectional area six times smaller than
conventional staplers, and articulates up to 80 degrees. The device uses
reloadable cartridges with a 30-millimeter staple line length. Laparoscopic
procedures today are primarily performed through 5- to 10-mm trocars ports. To
accommodate conventional stapling technology, however, surgeons are forced to
use 12- or 15-mm trocars, which can result in high post-operative pain, port
site infection or ventral hernias. These complications can prolong surgical
time, delay discharge, and result in unnecessary hospital readmissions. The
smaller cross-sectional area, diameter and much higher articulation of the
XCHANGE 30 platform are designed to allow easier access through smaller,
less-invasive ports, and to enable faster and easier access to vital organs
and tissue for key advanced laparoscopic procedures.

Cardicadesigns and manufactures proprietary stapling and anastomotic devices
for cardiac and laparoscopic surgical procedures.Cardica's technology
portfolio is intended to minimize operating time and enable minimally-invasive
and robot-assisted surgeries. Cardica manufactures and markets its automated
anastomosis systems, the C-Port^® Distal Anastomosis Systems and PAS-Port^®
Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery,
and has shipped over 46,400 units throughout the world. In
addition,Cardicais developing the Cardica^® MicroCutter XCHANGE™ 30, a
cartridge-based microcutter device with a five-millimeter shaft diameter, and
the Cardica^® MicroCutter XCHANGE™ 45, a cartridge-based microcutter device
with an eight-millimeter shaft. Both MicroCutter devices are designed to be
used in a variety of procedures, including bariatric, colorectal, thoracic and
general surgery. The Cardica MicroCutter XCHANGE 30 and XCHANGE 45 products
require 510(k) review and are not yet commercially available in the U.S.

Forward-Looking Statements
The statements in this press release regarding the expectation that Century
Medical looks forward to launching the MicroCutter XCHANGE 30 in Japan during
2014, and that Cardica anticipates that Japan will become an important market
for the MicroCutter XCHANGE 30, pending approval by the PMDA, are
"forward-looking statements." The words "expect," "anticipate" and "look
forward" are intended to identify these forward-looking statements. There are
a number of important factors that could cause Cardica's results to differ
materially from those indicated by these forward-looking statements,
including: that Cardica may not be successful in its efforts to further
develop or commercialize the XCHANGE 30 due to unanticipated technical or
other difficulties; that the XCHANGE 30 may face unanticipated development,
regulatory, or manufacturing delays; that review by the PMDA may take longer
than expected, or require additional unanticipated submissions or actions on
the part of Cardica or Century Medical; that Cardica's intellectual property
rights may not provide adequate protection to enable further development of
the XCHANGE 30; that surgeons may not use the XCHANGE 30 correctly, which
could cause unfavorable results that may impair the acceptance of the XCHANGE
30 by other surgeons; and that Cardica may not have sufficient funds to
develop the XCHANGE 30, as well as other risks detailed from time to time in
Cardica's reports filed with the U.S. Securities and Exchange Commission,
including its Current Report on Form 10-Q for the quarter endedMarch 31,
2013, under the caption "Risk Factors." Cardica expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein. You are encouraged to read
Cardica's reports filed with the U.S. Securities and Exchange Commission,
available at www.sec.gov.

SOURCE Cardica

Contact: Bob Newell, Vice President, Finance and Chief Financial Officer,
(650) 331-7133, investors@cardica.com
Press spacebar to pause and continue. Press esc to stop.